GlassScriptPhysician profile
Daryl J Silva
NPI 1306462106
$4,248.95
in general payments reported to CMS, 2019-2025
15 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,438 · 2022: $1,261 · 2023: $70.27 · 2024: $235 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eclipse Technology Solutions INC. | $1,214.66 | 2022 | |
| Prodigy Surgical Distribution, INC. | $1,200.00 | 2021 | |
| Liberty Surgical INC. | $1,200.00 | 2021 | |
| Amgen INC. | $138.68 | 2024-2025 | Krystexxa |
| Smith+Nephew, INC. | $85.53 | 2023-2024 | Grafix Pl, Versajet, Collagenase Santyl |
| Stryker Corporation | $70.99 | 2021-2022 | |
| Solventum Corporation | $58.46 | 2025 | Activ.A.C. |
| Averitas Pharma INC. | $57.14 | 2024 | Qutenza |
| Bioventus LLC | $55.35 | 2023-2025 | Exogen Ultrasound Bone Healing System, Exogen Ultrasound Bone Healing System |
| Kerecis Limited | $45.21 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbvie INC. | $34.99 | 2025 | |
| Organogenesis INC. | $28.72 | 2024 | |
| Ibsa Pharma INC. | $24.74 | 2024 | Tirosint, Licart |
| Horizon Therapeutics Plc | $21.41 | 2023 | Krystexxa |
| Depuy Synthes Sales INC. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.